IOncology

Editor's Note: The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluded successfully. At this conference, two studies from Professor Xichun Hu’s team at Fudan University Shanghai Cancer Hospital…

The Chinese Anti-Cancer Association, adhering to the tenet of "prevention, screening, diagnosis, treatment, and rehabilitation," has launched the "Chinese Tumor Integrated Diagnosis and Treatment Guidelines." At the 2024 CACA Integrated Breast Cancer Conference, "Oncology Frontier" invited three authoritative experts from internal medicine, surgery, and radiotherapy—Dr. Man Li from The Second Hospital of Dalian Medical University, Dr. Yingying Xu from The First Hospital of China Medical University, and Dr. Jiayi Chen from Ruijin Hospital, Shanghai JiaoTong University School of Medicine—to discuss the comprehensive management of breast cancer patients under the theme of "Integration for Prevention, Screening, Diagnosis, Treatment, and Rehabilitation." Under the moderation of Dr. Wei Li from Jiangsu Province Hospital, the three experts explored key aspects of comprehensive breast cancer management from personalized treatment, multidisciplinary collaboration, minimally invasive techniques, to new advancements in radiotherapy, providing valuable practical experience and theoretical guidance for future breast cancer management.

Editor's Note: With continuous advancements in medical research, treatment strategies for triple-negative breast cancer (TNBC) are also evolving. From June 14-16, 2024, the 5th Comprehensive Cancer Treatment Academic Conference of…

Hepatocellular carcinoma (HCC), the most common primary malignant liver tumor, is one of the leading causes of death in patients with cirrhosis. Non-invasive diagnostic tools such as transient elastography (FibroScan) have shown great promise in identifying patients at high risk of HCC. Recently, the 2025 EASL Liver Cancer Summit was held in Paris, France. Professor Abdel Ghani Atef from the Damas Liver & G.I.T Center in Egypt presented research on the value of ultrasound elastography in the early detection of HCC in patients with cirrhosis. To this end, a journalist from Oncology Frontier traveled to the summit and invited Professor Abdel Ghani Atef to have an in-depth discussion on topics such as the role of FibroScan in HCC screening and the significance of liver stiffness measurement cutoff values.

A recent study published in JNCI Cancer Spectrum (Jan 2025) introduces a machine learning-based cancer-specific cardiovascular disease (CVD) risk score, designed to improve risk prediction for breast, colorectal, and lung…

A newly published study in ESMO Open (Jan 2025) led by H. S. Rugo, R. M. Layman, F. Lynce, G. Curigliano, A. Brufsky, and colleagues analyzed real-world overall survival (OS)…

From July 5th to 7th, the "2024 Annual Progress Seminar in Clinical Oncology in China (BOC)," hosted by the Chinese Society of Clinical Oncology (CSCO), was held in Guangzhou. The conference invited numerous domestic oncology experts to highlight the "2023 Annual Progress in Clinical Oncology in China" selected by CSCO. Additionally, it focused on the theme of the 2024 ASCO Annual Meeting, "The Art and Science of Cancer Care: From Comfort to Cure," and discussed and interpreted major research presented at ASCO. To gain in-depth insights into the relevant content and trends, "Oncology Frontier - Hematology Frontier" conducted an exclusive interview with Professor Donglu Zhao from the Harbin Institute of Hematology and Oncology, who provided an excellent analysis of these topics.